TARS
Tarsus Pharmaceuticals, Inc. · Healthcare · Market cap $3.6B
Insiders sold $6.7M net in the last 90 days ·6 sellers, 0 buyers· 9 of 10 sales under Rule 10b5-1 plans· latest Form 4 filed Sep 9, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$19.3M
reported sales (SEC code S)
Unique Insiders
9
in the rolling window
Latest filing
Sep 9, 2026
Lin Elizabeth Yeu
Tarsus Pharmaceuticals, Inc. (TARS) has 44 SEC Form 4 filings (79 transaction rows) in the rolling window, disclosed by 9 distinct insiders. Most recent filing: Sep 9, 2026.
Inside the rolling window, 9 insiders at Tarsus Pharmaceuticals, Inc. reported no open-market purchases and 40 open-market sales totaling $19.3M. The most active filer is President/CEO and Board Chair Azamian Bobak R. with 8 filings. Insiders have net sold $14.0M over the trailing 6 months. The most recent open-market filing is a sale of 13,953 shares by Chief Medical Officer Lin Elizabeth Yeu, dated Sep 4, 2026, worth $1.2M.
- Industry:Biotechnology
- CEO:Bobak R. Azamian
- Employees:370
- HQ:Irvine, CA, US
- IPO:2020-10-16
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Medical Officer | Sale | 13,953 | $1.2M | Sep 9 | -2.0% | SEC ↗ | |
| President/CEO and Board Chair | Sale | 10,000 | $906K | Sep 9 | -2.0% | SEC ↗ | |
Neervannan SeshadriFirst in 6 months | Chief Operating Officer | Sale | 4,564 | $388K | Sep 9 | -2.0% | SEC ↗ |
| President/CEO and Board Chair | Sale | 10,000 | $801K | Sep 3 | -2.5% | SEC ↗ | |
Lin Elizabeth YeuFirst in 6 months | Chief Medical Officer | Sale | 4,601 | $340K | Sep 3 | -2.5% | SEC ↗ |
Lin Elizabeth YeuFirst in 6 months | Chief Medical Officer | Sale | 6,977 | $558K | Sep 3 | -2.5% | SEC ↗ |
Azamian Bobak R.First in 3 months | President/CEO and Board Chair | Sale | 10,000 | $615K | Jun 22 | — | SEC ↗ |
LINK WILLIAM J PHDFirst in 3 months | Director | Sale | 12,500 | $776K | Jun 17 | — | SEC ↗ |
Farrow Jeffrey SFirst in 3 months | See Remarks | Sale | 14,396 | $877K | Jun 17 | — | SEC ↗ |
Goodrich KatherineFirst filing | Director | Sale | 2,954 | $183K | Jun 17 | — | SEC ↗ |
| Chief Operating Officer | Sale | 2,989 | $200K | Mar 24 | — | SEC ↗ | |
| Chief Human Resources Officer | Sale | 4,029 | $280K | Mar 19 | — | SEC ↗ | |
| Chief Human Resources Officer | Sale | 4,071 | $280K | Mar 19 | — | SEC ↗ | |
| Chief Human Resources Officer | Sale | 4,174 | $280K | Mar 19 | — | SEC ↗ | |
Mottiwala AzizFirst filing | Chief Commercial Officer | Sale | 4,286 | $298K | Mar 19 | — | SEC ↗ |
Mottiwala AzizFirst filing | Chief Commercial Officer | Sale | 4,330 | $298K | Mar 19 | — | SEC ↗ |
Mottiwala AzizFirst filing | Chief Commercial Officer | Sale | 4,440 | $297K | Mar 19 | — | SEC ↗ |
| Chief Operating Officer | Sale | 3,125 | $217K | Mar 19 | — | SEC ↗ | |
| Chief Operating Officer | Sale | 3,610 | $248K | Mar 19 | — | SEC ↗ | |
| Chief Operating Officer | Sale | 4,589 | $307K | Mar 19 | — | SEC ↗ | |
Farrow Jeffrey SFirst filing | See Remarks | Sale | 2,111 | $147K | Mar 19 | — | SEC ↗ |
Farrow Jeffrey SFirst filing | See Remarks | Sale | 2,133 | $147K | Mar 19 | — | SEC ↗ |
Farrow Jeffrey SFirst filing | See Remarks | Sale | 2,186 | $146K | Mar 19 | — | SEC ↗ |
Lin Elizabeth YeuFirst in 3 months | Chief Medical Officer | Sale | 375 | $26K | Mar 19 | — | SEC ↗ |
Lin Elizabeth YeuFirst in 3 months | Chief Medical Officer | Sale | 379 | $26K | Mar 19 | — | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does TARS have?
Tarsus Pharmaceuticals, Inc. (TARS) has 44 SEC Form 4 filings (79 transaction rows) in the rolling 365-day window, disclosed by 9 distinct insiders. Most recent filing: Sep 9, 2026.
When was the most recent SEC Form 4 filing for TARS?
The most recent Form 4 filing for TARS on Tracefour is dated Sep 9, 2026.
Who is the most active insider at TARS?
The most active SEC Form 4 filer at TARS in the rolling window is President/CEO and Board Chair Azamian Bobak R., with 8 filings.
What is the net insider flow at TARS over the last 6 months?
Over the trailing 180 days, insiders at TARS have net sold $14.0M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at TARS in the current window?
Inside the rolling window, insiders at TARS bought $0 and sold $19.3M based on SEC Form 4 filings.
Can I get alerts for TARS insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Tarsus Pharmaceuticals, Inc. (TARS). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Tarsus Pharmaceuticals, Inc. is in the Healthcare sector.